Researchers found that genetically disrupting this pathway, or using the FDA - approved
Src kinase inhibitor dasatinib, increases PUMA levels and decreases tumor progression and metastasis in mice by up to fivefold.
These studies will investigate whether
Src kinase inhibitors are best used in the adjuvant setting post-surgery or after chemotherapy to prevent the formation of local and distant disease recurrence.
In the study, the authors suggest that using
Src kinase inhibitors may be more effectively used as adjuvant therapies to block αvβ3 signaling and prevent disease spread.
Not exact matches
Autophagy blockade sensitizes prostate cancer cells towards
Src family
kinase inhibitors.
This discovery led him to evaluate second generation Abl
kinase inhibitors, such as the dual
Src / Abl
inhibitor dasatinib, which received fast - track approval at the FDA in June 2006.